Author

Alistair J. Henry

UCB Pharma (United Kingdom)ORCID 0000-0002-9081-1055Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

Alison V. TurneriD· 1 shared Andrew G. Popplewell· 1 shared ANDREZA ESTEFANY DA SILVA OLIVEIRAiD· 1 shared Annelies Van HeckeiD· 1 shared Annette OhnemusiD· 1 shared Bert SchepensiD· 1 shared Birgit WeynandiD· 1 shared Bruno DombrechtiD· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Alison V. TurnerORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents

Bert Schepens, Loes van Schie, Wim Nerinckx, Kenny Roose, Wander Van Breedam, Daria Fijałkowska, Simon Devos, Wannes Weyts, Sieglinde De Cae, Sandrine Vanmarcke, Chiara Lonigro, Hannah Eeckhaut, Dries Van Herpe, Jimmy Borloo, ANDREZA ESTEFANY DA SILVA OLIVEIRA, , Xavier Saelens

The paper describes the development of a broadly neutralizing antibody, XVR011, effective against SARS-CoV-2 and its variants in animal models.

bioRxiv · Mar 8, 2021 · PreprintMolecular Biology